Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Recruiting NCT06999434

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Conditions: Demyelinating Disorders, MCI, Alzheimer's Disease (AD), MS (Multiple Sclerosis), SCI - Spinal Cord Injury, Spinal Radiculopathy

Sex: All

Ages: 18 Years – 90 Years

Healthy volunteers: Yes

Phase: PHASE1

Enrollment: 105

Sponsor: Yale University

Location: Yale University PET Center New Haven Connecticut

Summary

The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

Eligibility Criteria

Inclusion: 1. Male and Female subjects must be ≥18 and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06999434). StuddyBuddy aggregates publicly available trial information.